Systemic administration of dendrimer N‐acetyl cysteine improves outcomes and survival following cardiac arrest
| Autor: | Yu Guo, Elizabeth S Khoury, Rangaramanujam M. Kannan, Rishi Sharma, Hiren R. Modi, Sujatha Kannan, Nitish V. Thakor, Qihong Wang, Sarah J. Olmstead, Nirnath Sah, Payam Gharibani |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Acetyl cysteine
business.industry Biomedical Engineering Pharmaceutical Science Inflammation cardiac arrest RM1-950 Pharmacology dendrimer Chemical engineering inflammation Dendrimer medicine Systemic administration N‐acetyl cysteine rat TP155-156 Therapeutics. Pharmacology medicine.symptom business Research Articles TP248.13-248.65 Research Article Biotechnology |
| Zdroj: | Bioengineering & Translational Medicine, Vol 7, Iss 1, Pp n/a-n/a (2022) Bioengineering & Translational Medicine |
| ISSN: | 2380-6761 |
| Popis: | Cardiac arrest (CA), the sudden cessation of effective cardiac pumping function, is still a major clinical problem with a high rate of early and long‐term mortality. Post‐cardiac arrest syndrome (PCAS) may be related to an early systemic inflammatory response leading to exaggerated and sustained neuroinflammation. Therefore, early intervention with targeted drug delivery to attenuate neuroinflammation may greatly improve therapeutic outcomes. Using a clinically relevant asphyxia CA model, we demonstrate that a single (i.p.) dose of dendrimer‐N‐acetylcysteine conjugate (D‐NAC), can target “activated” microglial cells following CA, leading to an improvement in post‐CA survival rate compared to saline (86% vs. 45%). D‐NAC treatment also significantly improved gross neurological score within 4 h of treatment (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text